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Abstract
A workshop, ‘‘Chemopreventive properties of nonster-
oidal anti - inflammatory drugs (NSAIDs): Role of COX-
dependent and -independent mechanisms,’’ sponsored
by the Chemical and Physical Carcinogenesis Branch,
Division of Cancer Biology of the National Cancer
Institute, was held in Rockville, Maryland, on January
8, 2001. The workshop was composed of two parts: oral
presentations by a series of speakers, and a group
discussion of preselected topics.
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Background
Multiple lines of evidence suggest that nonsteroidal anti -
inflammatory drugs (NSAIDs) reduce the risk of colorectal
cancer and possibly other types of cancer. Results from
genetic and pharmacological studies suggest that the
antitumor effects of NSAIDs are mediated, at least in part,
through inhibition of cyclooxygenase (COX), the rate- limit-
ing enzyme in prostaglandin (PG) biosynthesis. However,
other results suggest that the chemopreventive effects of
NSAIDs are also mediated through COX- independent
mechanisms. Thus, the workshop was designed to bring
together investigators working in this area to: 1) evaluate
recent experimental evidence supporting COX-dependent
and - independent mechanisms underlying the chemopre-
ventive activity of NSAIDs; 2) identify important issues that
need to be resolved to clarify and enhance our understanding
of these mechanisms; 3) define the directions for future
research to advance the field; and 4) encourage collabo-
ration among investigators using the National Cancer
Institute (NCI) Activities to Promote Research Collaborations
initiative.
COX-Dependent Mechanisms
Raymond DuBois (Vanderbilt University, Nashville, TN)
discussed evidence suggesting that the anticancer effects
of NSAIDs are mediated through COX-dependent mecha-
nisms [1]. He emphasized that in population-based studies,
the intake of low doses of aspirin reduced the incidence of
colorectal cancer. This finding suggests that the protective
effect of aspirin is mediated through inhibition of COX. Dr.
DuBois suggested that COX-2 was an important pharmaco-
logical target of NSAIDs. He noted that increased amounts of
COX-2 are detected in various solid tumors including
colorectal cancer [2 ]. Overexpression of COX-2 appears to
be a consequence of increased transcription [3] and possibly
enhanced stability of COX-2 message [4]. The discovery of
a correlation between amounts of COX-2 in human lung and
colon cancers and patient prognosis was cited as further
evidence of the potential importance of COX-2 as a target
for therapy [5,6]. Dr. DuBois noted that overexpression of
COX-2 in intestinal epithelial cells inhibited apoptosis and
stimulated angiogenesis — properties that enhance tumori-
genesis [7,8 ]. Finally, he indicated that his group had shown
that treatment with a selective COX-2 inhibitor suppressed
the growth of experimental colorectal carcinoma without
detrimental effects to the normal intestine [9].
Jaime Masferrer (Pharmacia Co., St. Louis, MO) pre-
sented evidence that celecoxib, a selective COX-2 inhibitor,
reduced tumor growth and metastasis in xenograft tumor
models [10]. He suggested that the antineoplastic activity of
celecoxib can be explained, in part, by inhibition of angio-
genesis [8,10]. This idea was supported by several findings.
The observation that PGs stimulate the production of
vascular endothelial growth factor (VEGF) was reviewed
[11]. Additionally, Dr. Masferrer indicated that COX-2 was
expressed in the neovasculature of transplantable tumors in
experimental animals. His laboratory also showed that
celecoxib blocked basic fibroblast growth factor– induced
neovascularization and PG biosynthesis in the rat cornea
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[10]. Inhibition of neovascularization was associated with
decreased cell proliferation and increased apoptosis.
Daniel Simmons (Brigham Young University, Provo, UT)
discussed results demonstrating that nucleobindin (Nuc)
can bind COX when Nuc and COX-1 or COX-2 were
ectopically coexpressed in COS-1 cells [12]. Nuc has been
postulated to function in apoptosis as well as to control
calcium homeostasis in the cis -Golgi. Although the func-
tional significance of Nuc–COX interaction is unknown, this
could represent a PG- independent signaling mechanism. In
theory, NSAIDs could bind to COX and thereby alter
protein–protein interactions.
Daniel Hwang (Pennington Biomedical Research Center,
Baton Rouge, LA) presented evidence that COX-2 gene
expression could be a target of NSAIDs via PG-independent
mechanisms. He noted that certain NSAIDs, such as
flufenamic acid and sulindac sulfide, inhibited cytokine-
mediated induction of COX-2 in HT-29 human colon cancer
cells [13]. This suppressive effect was mediated, at least in
part, through inhibition of NF-B. NSAIDs that inhibited NF-
B signaling also suppressed mitogen- induced expression
of COX-2 and other proinflammatory molecules including
iNOS and IL-1 in macrophage- like RAW 264.7 cells.
Macrophages, an important stromal cell in tumor tissues, can
release cytokines that, in turn, stimulate the expression of
COX-2 in tumor cells and other stromal cells. Possibly,
NSAIDs inhibit both the production of cytokines by macro-
phages, and the induction of COX-2 by tumor cells in
response to cytokines. Dr. Hwang postulated that NSAIDs
may act not only by inhibiting COX enzyme activity but also
by suppressing the expression of COX-2 and other proin-
flammatory gene products [13].
COX-Independent Mechanisms
Although there is convincing evidence that overexpression of
COX-2 is linked to tumorigenesis, it is not clear whether the
antitumor effects of NSAIDs result entirely from inhibition of
COX activity. For example, high concentrations of NSAIDs
inhibit the growth of cell lines that do not express either
COX-1 or COX-2 [14]. Several investigators described
COX- independent effects of NSAIDs that may contribute to
the anticancer activity of these agents.
I. Bernard Weinstein (Columbia University, New York,
NY) reported that sulindac sulfone, a metabolite of the
NSAID sulindac that does not inhibit COX activity, induces
growth inhibition and apoptosis in cancer cell lines and also
inhibits tumorigenesis in experimental animals [15–18].
Moreover, sulindac sulfone was evaluated in patients with a
history of prostate cancer and rising serum PSA levels.
Sulindac sulfone–treated patients displayed a significant
decrease in PSA levels compared with the placebo control
group. Mechanistic studies done by his group in collaboration
with investigators at Cell Pathways, Inc. showed that
sulindac sulfone and related compounds induced apoptosis
through inhibition of cGMP-specific phosphodiesterases
PDE2 and PDE5. This led, in turn, to increased levels of
cGMP and activation of protein kinase G [17]. Activation of
protein kinase G then induces apoptosis, at least in part,
through activation of JNK1 [18].
Richard Gaynor (University of Texas Southwestern
Medical School, Dallas, TX) reviewed evidence that selected
NSAIDs block the activation of NF-B. The NF-B tran-
scription factors regulate the expression of a spectrum of
genes implicated in both inflammation and carcinogenesis.
He reported that aspirin and salicylate inhibited the activity of
IKK, thereby preventing IB phosphorylation and NF-B
activation [19]. In addition, sulindac sulfide inhibited both
IKK and IKK kinase activity and induced apoptosis in a
colon cancer cell line (HCT-15) that lacks COX-2. By
contrast, neither indomethacin nor ibuprofen inhibited IKK
kinase activity. These results suggest that in addition to
inhibiting COXs, selected NSAIDs may target the NF-B
pathway. Evidence was also presented of potential cross-
talk between the NF-B and  -catenin pathways. Hence,
NSAIDs may directly or indirectly alter a variety of signal
transduction pathways that are implicated in cancer.
Kenneth Kinzler and colleagues (Johns Hopkins, Balti-
more, MD) have identified other molecular targets of
NSAIDs. He reported that the apoptotic response to the
chemopreventive agent, sulindac, and other NSAIDs was
completely abolished in human colorectal cancer cells that
lack functional BAX [20]. NSAIDs inhibited the expression of
the antiapoptotic protein, Bcl -XL, resulting in a substantial
increase in the ratio of BAX:Bcl -XL and subsequent
apoptosis through a mitochondrial pathway [20]. In addition,
he reported that PPAR is one of the targets of both APC and
NSAIDs in human colorectal cancer cells [21]. Normally,
APC downregulates the expression of PPAR. Hence,
increased amounts of PPAR are detected frequently in
colorectal cancers because APC mutations are common in
this disease. Treatment with NSAIDs, such as sulindac
sulfide and indomethacin, compensated, in part, for an APC
mutation by disrupting the DNA binding activity of PPAR.
Furthermore, overexpression of PPAR partially rescued
colorectal cancer cells from sulindac sulfide– induced apop-
tosis. To more fully evaluate the role of PPAR in mediating
sulindac sulfide– induced apoptosis, additional experiments
were performed. Genetic disruption of PPAR in a human
colorectal cancer cell line did not alter the sensitivity of the
cells to NSAIDs [22]. When inoculated as xenografts in nude
mice, PPAR  / cells exhibited a decreased ability to
form tumors compared with PPAR + / and wild- type
controls [22]. These results suggest that PPAR is a
promising target for drug development. Once the relationship
between in vitro apoptosis caused by NSAIDs and in vivo
chemoprevention is better understood, the significance of
NSAID-mediated inhibition of PPAR should become
clearer.
NCI Research Plans for NSAIDs
Ernest Hawk of the NCI presented an overview of the current
status and future plans for NSAIDs as chemopreventive and
therapeutic agents with respect to NCI’s research portfolio.
Despite an impressive body of mechanistic, observational,
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and experimental evidence demonstrating the anticancer
properties of NSAIDs, these agents are not routinely
prescribed for cancer prevention because of several
fundamental deficits in our knowledge. It is not known which
specific agent(s) is most effective, or importantly, what dose
or length of treatment should be recommended for cancer
prevention. In addition, traditional NSAIDs are associated
with several well -known risks, including gastric ulceration,
renal and platelet dysfunction, making them less appealing
for preventive as opposed to therapeutic applications.
Attempts to improve the therapeutic index ( i.e., benefit:risk
ratio) of COX inhibitors include: 1) testing agents with
greater mechanistic specificity such as COX-2 selective
inhibitors (or other NSAID derivatives); 2) performing careful
downward dose titrations of traditional COX inhibitors; 3)
applying COX inhibitors regionally rather than systemically;
and 4) testing COX inhibitors in combination with other
chemopreventive agents.
Looking to the future, the NCI has a substantial research
portfolio related to the identification, testing, and develop-
ment of NSAIDs and NSAID derivatives as preventive
agents. This portfolio includes: 1) basic science studies to
further elucidate the key mechanisms(s) associated with
NSAID efficacy; 2) preclinical studies of various NSAIDs to
establish their efficacy against preinvasive and invasive
neoplasia; and 3) clinical trials evaluating NSAIDs, COX-2
selective inhibitors, NSAID derivatives, and corticosteroids
(which inhibit the expression of COX-2) in several different
cohorts at risk for cancer of the colorectum, duodenum,
esophagus, oral mucosa, lung, skin, or prostate. While the
NCI has focused on cancer prevention, it is important to
recognize that COX inhibitors offer several other potential
health benefits including analgesia, cardiovascular preven-
tion, and possibly, preventive effects in cognitive disorders
(e.g., Alzheimer’s disease). Indeed, the appropriate admin-
istration of NSAIDs, COX-2 selective inhibitors, or both in
persons at risk for these common diseases is a challenging
research endeavor, which has the potential for significant
public health rewards.
Group Discussion Session: Key Issues and Questions
1. Abundant evidence suggests that COX is one of the critical
targets that mediate the chemopreventive and antitumor
effects of NSAIDs. A key question then is whether over-
expression of COX in vivo is sufficient to induce tumori-
genesis. COX-2 has been reported to be important in
mediating angiogenesis, immune suppression, and resist-
ance to apoptosis. These effects can be reversed by
treatment with an NSAID. What is the relative importance
of these different effects? Could they differ in the colon
versus other tissues, e.g., lung?
Timothy Hla (University of Connecticut School of Medi-
cine, Farmington, CT) reported that overexpression of COX-
2 in mammary tissue was sufficient to cause breast cancer in
multiparous mice [23]. Susan Fischer (MD Anderson
Cancer Center, Science Park, TX) reported that transgenic
expression of COX-2 under the control of the keratin 14
promoter led to prostatic lesions consistent with prostatic
intraepithelial neoplasia. These findings support the idea that
COX-2 may represent a pharmacological target in several
premalignant and malignant conditions in addition to color-
ectal neoplasia.
Steven Dubinett (UCLA School of Medicine, Los Angeles,
CA) discussed evidence that overexpression of COX-2 in
tumor cells can inhibit cell -mediated immunity [24–27]. He
reported that elevated production of PGE2 by tumor cells
enhanced the production of IL -10 by lymphocytes and
macrophages while simultaneously inhibiting the production
of IL-12 by macrophages. IL-10 inhibits important aspects of
cellular immunity, whereas IL-12 induces type 1 cytokine
production and effective antitumor cell -mediated responses.
Moreover, abrogation of COX-2 expression was found to
promote antitumor reactivity by restoring the balance of IL-
10 and IL-12 in vivo. Taken together, these findings indicate
that COX-2–derived PGs can have important immunomo-
dulatory effects that are protumorigenic. The relative
importance of these immunosuppressive effects, compared
with other known effects of PGs, e.g., stimulation of
angiogenesis or inhibition of apoptosis, remains uncertain.
Whether different mechanisms are operative in different
malignancies or stages of carcinogenesis continues to be
investigated.
2. Is COX-1, in addition to COX-2, linked to tumori-
genesis? Although the design of the clinical studies differ,
celecoxib may have been less effective than sulindac in
causing regression of adenomas in subjects with FAP
[28,29]. How important, therefore, is COX-1 inhibition for
understanding the activity of NSAIDs?
Overexpression of COX-2 has been observed in numer-
ous human malignancies. COX-1 is normally expressed in
most cells and its kinetic parameters are virtually identical to
those of COX-2. Hence, knocking out the COX-2 gene or
selectively inhibiting COX-2 is not anticipated to completely
block the synthesis of prostanoids in tumor tissues. It is
logical to wonder, therefore, whether NSAIDs that are dual
COX-1/COX-2 inhibitors will be more effective antitumor
agents than selective inhibitors of COX-2.
Robert Langenbach (NIEHS, Research Triangle Park,
NC) reported that homologous disruption of either COX-1 or
COX-2 reduced polyp formation in Min/ + mice by about
80% [30]. PGE2 levels were increased in polyps compared
with normal tissue, and both COX-1 and COX-2 contributed
to the PGE2 that was produced. These results suggest that
COX-1, in addition to COX-2, plays a significant role in
intestinal tumorigenesis and that COX-1 may also be a
target of NSAIDs. Jaime Masferrer mentioned that his group
had found that selective inhibitors of COX-2 were more
effective than traditional NSAIDs in suppressing tumor
growth in xenograft models. Robert Langenbach indicated
that selective inhibitors of COX-2 were not always more
effective than dual COX-1/COX-2 inhibitors. He also
pointed out that there was a fundamental difference between
studies of xenografted tumors and his knockout experiments.
In the xenograft model, tumor cells are transplanted and
hence COX inhibitors must suppress tumorigenesis by
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reducing tumor growth. By contrast, in his COX knockout
experiments, the formation of endogenous tumors was
assessed. In this instance, COX deficiency could reduce
tumor formation because of inhibitory effects on the initiation
or promotion stages of tumorigenesis.
3. Although the antitumor effects of NSAIDs are well
documented, there is debate as to the relative importance of
COX-dependent versus COX-independent mechanisms of
action. How convincing is the evidence that the antitumor
effects of NSAIDs are mediated, in part, by PPARs or
inhibition of cGMP phosphodiesterases? Are changes in
intracellular levels of arachidonate important for mediating
the antitumor effects of NSAIDs? What are the limitations of
the data suggesting that NSAIDs may mediate their
anticancer effects, in part, by COX- independent mecha-
nisms? Are there experiments that can be done to help
resolve this issue?
If the antitumor effects of NSAIDs are mediated, in part,
through COX- independent pathways, the key question is
‘‘What are the other potential molecular targets of NSAIDs?’’
PPARs represent one possible target. NSAIDs can activate
PPAR and  [31] — nuclear receptors that regulate the
transcription of a diverse array of genes including those
involved in inflammation and growth. Several in vitro studies
have shown that ligands of PPAR inhibit the growth of
various cancer cell lines [32,33]. Consistent with these
findings, the growth of cancer cell lines transplanted into
nude mice is suppressed by treatment with PPAR ligands
[34]. These findings suggested that activating PPAR could
protect against tumor formation. However, conflicting results
were obtained in pharmacological studies in Min mice
[35,36]. In this model, treatment with a PPAR ligand led
to a modest increase in the number of colonic polyps — an
effect that was not observed in prior studies of either NSAIDs
or selective COX-2 inhibitors [37,38].
Geoffrey Girnun, a member of Bruce Spiegelman’s
laboratory (Dana-Faber Cancer Institute, Boston, MA),
presented new evidence that PPAR could represent a
pharmacological target for inhibiting colorectal cancer. He
reported the effects of treating PPAR wild- type and PPAR
( + / ) mice with azoxymethane, a well -known colon
carcinogen. PPAR ( + / ) mice developed colorectal
cancer faster than PPAR wild- type mice. There were also
a greater number of tumors/mouse in the PPAR hetero-
zygous mice. These data suggested that PPAR could
represent a tumor-suppressor gene. Possibly, high doses of
NSAID cause an endogenous PPAR ligand to accumulate,
which, in turn, activates PPAR. Questions were raised
about the possible identity of an endogeneous PPAR
ligand, but this remains uncertain.
These results and those presented by Dr. Kinzler suggest
that PPAR and  could be relevant targets of NSAIDs. The
observation that NSAIDs activate PPAR while inhibiting
PPAR raised some critical questions relating to how
NSAIDs modulate the activity of different PPARs and the
target genes that are differentially expressed. It was agreed
that further research is needed to 1) establish the importance
of PPARs as therapeutic targets for preventing or treating
cancer and 2) determine whether the antitumor effects of
NSAIDs are mediated, in part, by effects on PPARs.
Joseph Thompson (Cell Pathways, Inc., Horsham, PA)
stressed that sulindac sulfone, a metabolite of sulindac that
does not inhibit COX, induced apoptosis by inhibiting cGMP
phosphodiesterases. These findings raise additional ques-
tions that should be answered. For example, do other
inhibitors of cGMP phosphodiesterases induce apoptosis?
Which NSAIDs, if any, inhibit cGMP phosphodiesterases and
induce apoptosis?
Frank Fitzpatrick (University of Utah, Salt Lake City, UT)
stated that recent work in the laboratory of Stephen Prescott
suggests that NSAIDs induce apoptosis by causing free
arachidonic acid to accumulate, rather than simply inhibit the
production of PGs [39]. This idea is based on several lines of
evidence: 1) exogenous arachidonic acid caused apoptosis
in colon cancer and other cell lines; and 2) triacsin C, an
inhibitor of fatty acid–CoA lipase (FACL4), an arachidonic
acid–utilizing enzyme, induced apoptosis. Additionally,
overexpression of FACL4 or COX-2 as ‘‘sinks’’ for unesteri-
fied arachidonic acid blocked apoptosis; and 3) treatment
with indomethacin and sulindac enhanced the apoptosis-
inducing effect of triacsin C. It was concluded that modulating
the cellular level of unesterified arachidonic acid is a general
mechanism by which apoptosis is regulated, and that COX-2
and FACL4 promote carcinogenesis by lowering the level of
free arachidonic acid. Hence, NSAIDs could inhibit tumori-
genesis, in part, by increasing the levels of unesterified
arachidonic acid in cells. Whether arachidonic acid or its
metabolites stimulate apoptosis is an important question that
requires additional investigation. Additional research will be
required to understand howmuch of the anticancer activity of
NSAIDs can be attributed to reduced PG production versus
increased levels of arachidonate in cells.
Jilly Evans (Merck Research Laboratories, West Point,
PA) reviewed both genetic [40] and pharmacological [41]
data suggesting that COX-2 is the primary target of NSAIDs.
She cited evidence that knocking out the COX-2 gene
protected against intestinal tumorigenesis in a murine model
of familial adenomatous polyposis [40]. Moreover, rofecoxib,
a selective COX-2 inhibitor, at blood concentrations equiv-
alent to those achieved in humans at clinical steady-state
dosing of 25 mg, once per day, decreased polyp number by
55% in Apc716 mice [41]. Rofecoxib was at least as
effective as sulindac in inhibiting polyp number; it also
reduced DNA replication and amounts of VEGF in polyps.
Lawrence Marnett (Vanderbilt University, Nashville, TN)
also discussed findings from his laboratory suggesting the
importance of COX-2 as a therapeutic target. He com-
mented on the development of o - (acetoxyphenyl )hept-2-
ynyl sulfide (APHS), an aspirin- like molecule that covalently
inactivates COX-2 [42]. Relative to aspirin, APHS was
60 times as reactive against COX-2 and 100 times as
selective for its inhibition. The effects of APHS on the growth
of colon cancer cell lines were assessed in soft agar.
Consistent with the idea that COX-2 is important for the
growth of tumor cells, APHS inhibited the growth of a colon
cancer cell line (HCA-7) expressing COX-2. By contrast,
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APHS did not inhibit the growth of a colon cancer cell line
(HCT-15) that does not express COX-2.
Several investigators raised concerns that the evidence
supporting the COX- independent effects of NSAIDs was
based primarily on results in which very high concentrations
of NSAID were used in vitro. Raymond DuBois and Andrew
Dannenberg questioned the clinical relevance of experi-
ments demonstrating that high concentrations (>100 M) of
NSAIDs stimulate apoptosis in vitro. They pointed out that
much lower concentrations of NSAIDs are usually detected
in the serum of patients given standard doses of NSAIDs.
This issue was also raised by Jaime Masferrer who noted
that 200 to 300 M indomethacin was required to suppress
cell proliferation in vitro, whereas plasma concentrations of
this drug are much lower. Despite these concerns, other
participants felt that the concentrations of NSAIDs used in
at least some of the in vitro experiments were clinically
relevant. For example, Daniel Hwang noted that the
concentrations of NSAIDs that suppress cytokine-mediated
induction of COX-2 in vitro are clinically attainable. He
indicated that 1 g of mefenamic acid given four times daily
produced steady-state concentrations of 80 M [43]. Rifat
Pamukcu (Cell Pathways, Inc. ) indicated that the concen-
trations of sulindac metabolites within the lumen of the
gastrointestinal tract are higher than those in plasma. He
also reported that both sulindac sulfone and sulindac sulfide
are sequestered within the cell; this results, in turn, in
intracellular concentrations of both sulindac metabolites that
appear to be substantially higher than observed in plasma.
Hence, some of the COX- independent mechanisms of
action may be clinically relevant for the metabolites of
sulindac.
A discussion ensued concerning the potential use of COX
knockout mice to determine whether clinically relevant doses
of NSAIDs reduce tumorigenesis, in part, by COX- inde-
pendent mechanisms. Lawrence Marnett suggested that it
would be worthwhile to evaluate whether selective COX-2
inhibitors suppressed tumorigenesis in COX-2 knockout
mice. If COX-2–selective inhibitors still show chemopre-
ventive effects, this would represent a COX-2–independent
effect of the agent. Robert Langenbach stated that this was a
good idea, but indicated that such studies were not easy to
perform because the number of tumors is low in COX-2
knockout mice in the first place.
4. In considering ongoing chemoprevention trials utilizing
NSAIDs or selective COX-2 inhibitors, what problems exist
concerning patient eligibility criteria? Should more effort be
made to correlate an individual’s clinical response with
known genetic polymorphisms for enzymes involved in the
metabolism of NSAIDs?
Maria Elena Martinez (Arizona Cancer Center, Tucson,
AZ) pointed out that use of aspirin is relatively common
among subjects who are potential participants in chemo-
prevention trials. For example, some individuals may use
low-dose aspirin to protect against cardiovascular disease. If
one excludes individuals who use aspirin regardless of dose,
subject recruitment will be extremely difficult and costly. If
use of low-dose aspirin is permitted, it is unclear whether the
therapeutic intervention will cause reductions in recurrence,
e.g., colorectal polyp formation, beyond those related to the
use of aspirin. Although there is no straightforward answer to
this dilemma, the group did not feel that there was compelling
evidence yet that low-dose aspirin protected against color-
ectal neoplasia. In clinical trials, stratifying patients according
to use of aspirin may prove helpful until further information is
available.
Dr. Martinez discussed preliminary findings concerning
the use of aspirin and colorectal adenoma recurrence
stratified by NAT2 genotype. The protective effect of aspirin
appeared to be stronger among slow acetylators than rapid
acetylators. This finding suggests that the efficacy of aspirin
in reducing the risk of colorectal neoplasia may be modified
by genetic polymorphisms of enzymes involved in the
metabolism of NSAIDs. Clearly, this is an important issue
that requires additional investigation.
Summary
There is abundant evidence that NSAIDs inhibit tumori-
genesis. The results of both genetic and pharmacological
studies suggest that inhibiting COX reduces the risk of
cancer. Although COX-2 is overexpressed in many malig-
nancies, more needs to be understood about the upstream
signaling pathways that regulate its expression. Additionally,
the mechanisms by which increased amounts of COX-2
predispose to cancer are incompletely understood. PGs can
stimulate angiogenesis and invasiveness while inhibiting
apoptosis and immune surveillance. The relative significance
of these different protumorigenic effects could vary in
different types of tumors or stages of carcinogenesis.
Additional insights should be gained by defining the down-
stream pathways that are activated by PGs via their
receptors. Further work is also needed to understand how
much of the anticancer activity of NSAIDs can be attributed
to inhibition of PG synthesis versus increased amounts of
unesterified arachidonic acid in cells.
NSAIDs or related metabolites can affect a variety of
molecular targets in addition to COX. Hence, the anticancer
activity of NSAIDs may also reflect COX- independent
effects. Examples of other possible pharmacological targets
include cGMP phosphodiesterases, PPARs, and NF-B. It
will be important to determine which of these COX-
independent mechanisms are operative in humans given
clinically relevant doses of NSAIDs. For example, high
concentrations of NSAIDs stimulate PPAR in cultured cells
but it is unknown whether PPAR activation occurs when
standard doses of NSAIDs are administered in vivo. Clearly,
additional studies of NSAIDs will be required to more fully
understand the relative importance of COX-dependent and
- independent mechanisms of action.
Another significant challenge will be to evaluate whether
NSAIDs and related compounds are more effective in
chemoprevention or cancer therapy when combined with
other agents. Preclinical studies combining inhibitors of
EGFR kinase or ornithine decarboxylase with NSAIDs
illustrate the promise of this approach [44,45]. Ultimately,
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continued research should provide a more complete under-
standing of the anticancer properties of NSAIDs as well as
insights that will permit the safe and effective use of these
agents in both preventing and treating cancer.
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